Form 4: Maravai LifeSciences Director Constantine Mihas Reports Significant RSU Grant

Maravai LifeSciences Holdings, Inc. Director Constantine S. Mihas reported the acquisition of 89,139 restricted stock units as part of an incentive plan.

Summary

• Constantine S. Mihas, a Director of Maravai LifeSciences Holdings, Inc. (MRVI), filed a Form 4 reporting a change in beneficial ownership.
• On June 16, 2025, Mr. Mihas acquired 89,139 shares of Class A Common Stock in the form of restricted stock units (RSUs).
• These RSUs were awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan.
• The RSUs are set to vest in full upon the earlier of one year from the grant date (June 16, 2025) or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.
• The reported price per share for this acquisition was $2.16.
• Following this transaction, Mr. Mihas beneficially owns a total of 138,055 shares of Class A Common Stock.
• The 138,055 shares are held for the benefit of a GTCR-affiliated entity, and Mr. Mihas disclaims any pecuniary interest in these securities.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation grant to a director, which is generally a positive sign for aligning interests and retention, but it does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units to a director aligns management's interests with shareholders, incentivizing long-term performance and retention.
• The award is part of an established incentive plan (2020 Omnibus Incentive Plan), indicating a structured approach to executive and director compensation.

Risks

• The actual value realized from the restricted stock units is contingent on the future market price of Maravai LifeSciences' Class A Common Stock, which could be lower than the grant price.
• The vesting schedule means the director's full ownership of the RSUs is contingent on continued service or specific future dates, introducing a time-based risk.

Future Outlook

The vesting schedule for the restricted stock units indicates a future milestone in 2026, tied to the company's annual meeting, which will determine the full ownership of these shares, aligning the director's long-term interest with the company's performance.

Management Comments

• "The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16."

Industry Context

This Form 4 filing is a routine insider transaction report, common across all publicly traded companies. The grant of restricted stock units is a typical form of equity compensation used in the life sciences industry, similar to other sectors, to incentivize long-term performance and align director interests with shareholders.

Comparison to Industry Standards

• The grant of restricted stock units to a director is a common practice in corporate governance across various industries, including life sciences, as a means of aligning executive and director incentives with shareholder value.
• While specific comparable companies or projects are not detailed in this Form 4, such equity awards are standard for directors at peer companies in the life sciences sector, such as Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), or Bio-Rad Laboratories (BIO), which also utilize similar incentive plans to retain and motivate key personnel.
• The specific value and vesting terms of this RSU grant would typically be assessed against peer group compensation disclosures to determine its competitiveness and alignment with industry benchmarks.

Related Party Transactions

• The 138,055 shares beneficially owned by the reporting person are held for the benefit of a GTCR-affiliated entity, and the reporting person disclaims pecuniary interest, indicating a relationship with GTCR, LLC.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director aligns their interests with shareholders by tying a portion of compensation to the company's stock performance, potentially encouraging long-term value creation.
• Management/Directors: The RSU grant serves as an incentive for the director to remain with the company and contribute to its long-term success, with the vesting schedule ensuring commitment.

Next Steps

• Vesting of the 89,139 restricted stock units upon the earlier of one year from June 16, 2025, or the date of the 2026 annual meeting of stockholders.

Key Dates

Keywords

Maravai LifeSciences, MRVI, Constantine Mihas, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, Director Compensation, Beneficial Ownership, GTCR